We have developed the proprietary method for analyzing ex vivo drug sensitivities (DS) of anticancer drugs.
Together with the functional and/or genomic characterization of the cancer cells, the DS results can be used in any of the following ways:
We offer a suite of customizable CRO services for drug candidates targeting human acute myeloid leukemia, non-Hodgkin lymphoma, or blood cancers in companion animals.
Are you interested in receiving a proposal from ImpriMed? Leave us a message and we will get back to you shortly.